-
Tytuł:
-
The previously common post-kidney transplant Kaposi sarcoma has become non-existent for a decade: an Egyptian experience.
-
Autorzy:
-
Donia AF; Nephrology and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. .
Fouda MA; Nephrology and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ghoneim ME; Nephrology and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Refaie AF; Nephrology and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ali-El-Dein B; Department of Urology, Faculty of Medicine, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
-
Źródło:
-
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 May; Vol. 147 (5), pp. 1493-1498. Date of Electronic Publication: 2020 Nov 01.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Berlin ; New York : Springer-Verlag.
-
MeSH Terms:
-
Kidney Transplantation/*adverse effects
Sarcoma, Kaposi/*epidemiology
Adult ; Cytomegalovirus/pathogenicity ; Cytomegalovirus Infections/metabolism ; Egypt/epidemiology ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Prevalence ; Retrospective Studies ; Sarcoma, Kaposi/metabolism ; Sarcoma, Kaposi/virology ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Transplant Recipients
-
References:
-
Ali Ibrahim M, Mansour Abdel-Rahman A, El-OkelyA M, Mohamed Goda T, HosnyZahran M, Refaie AF, Fouda MA, Ali Elsawy MA (2020) Three-year follow up of cytomegalovirus prophylaxis regimens in renal transplant recipients as an economy-saving strategy: a comparative study. Kidney Int Rep 5(3):S135. https://doi.org/10.1016/j.ekir.2020.02.341. (PMID: 10.1016/j.ekir.2020.02.341)
Bakr MA, Nagib AM, Abbas MH, Donia AF (2019) Conversion from twice-daily to once-daily tacrolimus among egyptian living-donor kidney allograft recipients: a single-center experience. ExpClin Transplant 17(5):594–598.
Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A (2008) Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 198(1):23–30. (PMID: 10.1086/588820)
Cattamanchi A, Saracino M, Selke S, Huang ML, Magaret A, Celum C, Corey L, Wald A, Casper C (2011) Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. J Med Virol 83(10):1696–1703. (PMID: 10.1002/jmv.22194)
Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D (2019) Kaposi sarcoma. Nat Rev Dis Primers 5(1):9. (PMID: 10.1038/s41572-019-0060-9)
Donia AF, Mostafa A, Refaie H, El-Baz M, Kamal MM, Ghoneim MA (2008) Postkidney Transplant malignancy in Egypt has a unique pattern: a three-decade experience. Transplantation 86:1139–1142. (PMID: 10.1097/TP.0b013e318187ccb3)
Francès C, Marcelin AG, Legendre CH, Chevret S, Dussaix E, Lejeune J, Euvrard S, Bigorie A, Schulz TF, Agbalika F, Lebbé C, Skin and Organ Transplantation Group of the French Society of Dermatology (2009) The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant 9(11):2580–2586. (PMID: 10.1111/j.1600-6143.2009.02816.x)
Gheith O, Bakr A, Wafa E, Fouda A, El Agroudy A, Refaie A, Donia A, Sabry A, Sobh M, Shokeir A, Ghoneim M (2007) Sirolimus for visceral and cutaneous Kaposi’s sarcoma in a renal-transplant recipient. ClinExpNephrol 11:251–254.
Ghoneim MA, Sobh MA, Shokeir AA, Bakr MA, el-Sherif A, Foda MA, (1993) Prospective randomized study of triple versus conventional immunosuppression in living related donor kidney transplantation. Transplant Proc 25(3):2243–2245. (PMID: 8516887)
Guo WX, Antakly T (1995) AIDS-related kaposi’s sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation. Am J Pathol 146(3):727–734. (PMID: 78874531869167)
Hamdy AF, El-Agroudy AE, Bakr MA, Moustafa A, El Baz M, El-M E-S, Ghoneim MA (2005) Comparison of sirolims with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 5(10):2531–2538. (PMID: 10.1111/j.1600-6143.2005.01064.x)
Kedes DH, Ganem D (1997) Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99(9):2082–2086. (PMID: 10.1172/JCI119380)
Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M, (2007) Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. ExpClin Transplant 5(2):673–679.
Oktafiani D, Megasari NLA, Fitriana E, Nasronudin LMI (2018) Detection of human herpesvirus-8 antigen in hiv-infected patients in east java, indonesia. Afr J Infect Dis 12(2):43–46. (PMID: 301092856085735)
Raedemaeker J, Marot L, Camboni A, Kanaan N (2019) Kaposi sarcoma after kidney transplantation. BMJ Case Rep 12(5):e229681. https://doi.org/10.1136/bcr-2019-229681. (PMID: 10.1136/bcr-2019-22968131061183)
Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA (2011) Alemtuzumab preconditioning allows steroidcalcineurin inhibitor-free regimen in live-donor kidney transplant. ExpClin Transplant 9(5):295–301.
Sheashaa H, Ismail A, Sobh MA, Ghoneim MA (2003) Basiliximab reduces the incidence of acute cellular rejection in live related donor kidney transplantation, Result of 3 years prospective randomized trail. J Nephrol 16:393–398. (PMID: 12832740)
Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD (2018) Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J 11(3):315–329. (PMID: 10.1093/ckj/sfx122)
Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352(13):1317–1323. (PMID: 10.1056/NEJMoa042831)
Wolf S, Hoffmann VS, Habicht A, Kauke T, Bucher J, Schoenberg M, Werner J, Guba M, Andrassy J (2018) Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS ONE 13(4):e0194975. https://doi.org/10.1371/journal.pone.0194975. (PMID: 10.1371/journal.pone.0194975296595885901925)
-
Contributed Indexing:
-
Keywords: Kaposi; Steroid-free; Transplant; Valacyclovir; mTOR inhibitor
-
Substance Nomenclature:
-
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
-
Entry Date(s):
-
Date Created: 20201101 Date Completed: 20210412 Latest Revision: 20211204
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00432-020-03433-1
-
PMID:
-
33130940
-
Background: De novo malignancy is a worrying complication after kidney transplantation; the type of which may vary due to factors such as the prevalence of viral infection and race. Kaposi sarcoma used to be the most common malignancy among our patients constituting more than one-third of cancers. Nevertheless, we noticed that Kaposi sarcoma has not been observed for a long period. Therefore, we conducted this study to explore such observation.
Methods: Data of all kidney transplant recipients were retrieved and retrospectively analyzed. Their total number was 3126 patients. Their mean age was 28.71 ± 10.97 years and of them, 823 (26.3%) were females. The pattern of Kaposi sarcoma throughout the last decade as well as the preceding three decades was studied. The possible relation between the disappearance of Kaposi sarcoma and three paradigm shifts in our practice, namely the use of mTOR inhibitors, steroid-free regimen and CMV prophylaxis was explored.
Results: Since 2010, no new cases of Kaposi sarcoma have been observed. In addition, patients who have been transplanted after 2006 did not develop such malignancy. Patients who received CMV prophylaxis and/or were maintained on mTOR inhibitor or steroid-free regimens have not developed Kaposi sarcoma. Moreover, CMV prophylaxis had a statistically significant difference when compared to a homogenous group without CMV prophylaxis. However, Kaplan-Meier analysis of patients of the three policies and their counterpart groups showed comparable results.
Conclusion: Kaposi sarcoma, which was previously the most common malignancy, is no longer observed for almost a decade among our kidney transplant recipients. m-TOR inhibitors, steroid-free regimen and CMV prophylaxis policy are possible contributing factors. Nevertheless, only CMV prophylaxis policy had a statistically significant relation to the disappearance of Kaposi sarcoma.